Clinical research

Impact of drug-eluting stent type on periprocedural myocardial necrosis

EuroIntervention 2011;7:136-142. DOI: 10.4244/EIJV7I1A22

Kohei Wakabayashi
Kohei Wakabayashi, MD; Cedric Delhaye, MD; Michael Mahmoudi, MD; Loic Belle, MD; Itsik Ben-Dor, MD; Michael A. Gaglia, Jr., MD, MSc; William O. Suddath, MD; Lowell F. Satler, MD; Kenneth M. Kent, MD, PhD; Augusto D. Pichard, MD; Joseph Lindsay, MD; Ron Waksman*, MD
Division of Cardiology, Washington Hospital Center, Washington, DC, USA

Aims: The relationship between stent design and periprocedural myocardial infarction is unclear. The newest type of drug-eluting stent (DES), the everolimus-eluting stent (E

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

clinical researchcreatine phosphokinase-mbpercutaneous coronary intervention
Read next article
Impact factors: scientific and career assessment by numbers

Latest news